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Semiconductor quantum dots (QDs) have recently been used to deliver and monitor biomolecules, such as drugs and proteins.
However, QDs alone have a low eﬃciency of transport across the plasma membrane. In order to increase the eﬃciency, we
used synthetic nona-arginine (SR9), a cell-penetrating peptide, to facilitate uptake. We found that SR9 increased the cellular
uptake of QDs in a noncovalent binding manner between QDs and SR9. Further, we investigated mechanisms of QD/SR9
cellular internalization. Low temperature and metabolic inhibitors markedly inhibited the uptake of QD/SR9, indicating that
internalization is an energy-dependent process. Results from both the pathway inhibitors and the RNA interference (RNAi)
technique suggest that cellular uptake of QD/SR9 is predominantly a lipid raft-dependent process mediated by macropinocytosis.
However, involvement of clathrin and caveolin-1 proteins in transducing QD/SR9 across the membrane cannot be completely
ruled out.

1. Introduction
Fluorescent semiconductor quantum dots (QDs) have been
used to deliver and monitor biomolecules into cells in the
past few years [1–3]. Advantages of QDs over traditional
dyes and proteins (e.g., green and red fluorescent proteins)
include their unique physical and chemical properties,
namely, photostability, high quantum yield, narrow emission
peak, exceptional resistance to degradation, broad sizedependent photoluminescence, and multiplexing potential
[4]. Although QDs can be engulfed by living cells, the use
of cell-penetrating peptides can increase uptake eﬃciency
[5].
The study of the uptake mechanism of QDs is just
beginning. Using specific inhibitors, Ruan et al. identified

macropinocytosis, actin filaments, and microtubules as
required for internalization and intracellular transport
of streptavidin-coated QD/Tat-biotin in HeLa cells [6].
Zhang and Monteiro-Riviere demonstrated that carboxylic
QDs were internalized by lipid raft-dependent endocytosis
in human epidermal keratinocytes, and these pathways
were primarily regulated by the G-protein-coupled receptor associated pathway and low-density lipoprotein receptor/scavenger receptor [7].
Cell-penetrating peptides (CPPs), also known as protein
transduction domains (PTDs) or membrane transduction
peptides (MTPs), have been used to transduce biologically
active proteins, siRNA, and drugs across plasma membranes
[8, 9]. The advantages of CPPs include ease of preparation, lack of toxicity to the cell, and high eﬃciency of
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transduction [10]. CPPs can enter cells with a half-time of
1.8 minutes, corresponding to a first-order rate constant
k of 0.007 sec−1 [11]. Among the basic CPPs, the cellular
uptake of polyarginine tends to be more eﬃcient than that
of polylysine, polyhistidine, or polyornithine [12]. The highest translocation eﬃciencies were achieved by using octaarginine or nona-arginine peptides [12]. The synthetic nonaarginine (SR9) peptide has been shown to eﬀectively deliver
not only covalently fused proteins but also noncovalently
bound protein into diﬀerent types of animal and plant cells
[9, 13].
The mechanism of cellular entry of CPPs has been the
focus of numerous studies. Early reports suggested that
CPPs delivery of molecules into cells was independent of
endocytosis, energy, receptors, or active transporters [14–
16]. However, it was later found that fixing cells may have
artificially transduced molecules across plasma membranes
[17]. More recent studies using live cell imaging suggested
the involvement of macropinocytosis [18, 19].
The goals of this study were to determine (1) whether
SR9 can noncovalently facilitate QD uptake and (2) the
internalization mechanisms for uptake of QD/SR9 complex.
We treated A549 cells with QDs alone or QD/SR9 complex to
determine the eﬃciency of QD/SR9 uptake. Inhibitors and
siRNA were used to identify molecules and processes that
contribute to the uptake.

2. Materials and Methods
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Figure 1: Gel retardation analysis of the interaction between QDs
and SR9. QDs were premixed with SR9 at diﬀerent molecular ratios.
Lane 1: QDs without SR9. Lanes 2–5: QDs mixed with SR9 at ratios
of 10, 20, 30, and 60, respectively. The decrease in mobility reflected
the formation of QD/SR9 complexes.

into 35 mm glass-bottom tissue culture plates (MatTek,
Ashland, MA, USA) at an initial confluency of 20% and
allowed to attach for 48 hours.

2.1. Quantum Dots. CdSe/ZnS quantum dots (Adirondack
Green, 520 nm) were purchased from Evident Technologies
(Troy, NK, USA). These quantum dots have a polyethylene
glycol (PEG) lipid surface coated with carboxyl terminal
groups. The emission and excitation peak wavelengths
are 520 nm and 505 nm, respectively. The hydrodynamic
diameter is 25 nm.

2.5. Gel Retardation Assay. The QD and SR9 mixtures were
prepared at diﬀerent molecular ratios (1 : 10, 1 : 20, 1 : 30, and
1 : 60) and then incubated for 20 min at room temperature to
allow noncovalent complexes to form. These complexes were
analyzed by electrophoresis in a 0.6% agarose gel in 0.5%
TAE buﬀer at 130 voltages for 60 min. The complexes were
visualized by UV light.

2.2. Nona-Arginines (SR9). Nona-arginines were synthesized
by solid-phase peptide synthesis (Sigma-Aldrich, Saint Louis,
MO, USA). The synthetic peptides were purified by high
performance liquid chromatography (HPLC) using a reverse
phase column. The purity of SR9 was ∼99%.

2.6. QD Uptake with SR9 at Diﬀerent Molecular Ratios. To
determine the optimal QD/SR9 ratio for eﬃcient delivery,
A549 cells were incubated with QD/SR9 at diﬀerent molecular ratios (1 : 10 to 1 : 60). The cells were washed with icecold phosphate buﬀered saline (PBS) six times to remove
unbound QD/SR9. Fluorescent images were then obtained
and quantified.

2.3. Chemicals. Fetal bovine serum, Ham’s F-12 medium
with L-glutamine, trypsin-EDTA (1x), penicillinstreptomycin, sucrose, sodium azide, sodium fluoride,
and chlorpromazine were purchased from Fisher Scientific
(Pittsburgh, PA, USA). Nystatin, filipin, 5-(N-ethyl-Nisopropyl) amiloride (EIPA), cytochalasin D (Cyt D),
antimycin A, and monodansylcadaverine (MDC) were
purchased from Sigma-Aldrich.
2.4. Cell Culture. The human bronchoalveolar carcinomaderived cell line (A549) was purchased from ATCC (Manassas, VA, USA). Cells were maintained in Ham’s F-12 medium
supplemented with 10% fetal bovine serum, 100 units/mL
penicillin, and 100 μg/mL streptomycin and grown at 37◦ C in
a 5% CO2 humidified environment. A549 cells were seeded

2.7. Cytotoxicity Measurement. To determine the cytotoxicity
of QD/SR9, A549 cells were treated with QD/SR9 (1 : 20)
at 12.5, 25, 50, 100, and 200 nM QD concentrations for 24
hours. Untreated cells served as a control group. The MTS
assay (Cell Titer 96 Aqueous One Solution Assay, Promega,
Madison, WI, USA) was used to determine cytotoxicity.
Absorbance was measured at 490 nm using a microplate
reader (FLOUstar, BMG Labtechnologies, Durham, NC,
USA).
2.8. Noncovalent Binding and Internalization of QDs and SR9.
QDs were premixed with SR9 peptides at the molecular
ratio of 1 : 20 at room temperature for 20 min. immediately

Journal of Biomedicine and Biotechnology
7

5

∗

α

α

α

∗

∗

4
3
2
1
0

100
75
50
25
0

1:10

1:20

1:30

1:40

1:50

1:60

Figure 2: QD uptake with SR9 at diﬀerent molecular ratios. QDs
were premixed with SR9 at molecular ratios from 1 : 10 to 1 : 60.
A549 cells were treated with QD/SR9. Values are mean ± SD
from three independent experiments. Fluorescence intensity is
normalized relative to the value at 1 : 10. ∗ P < .01 versus 1 : 10;
α P < .01 versus 1 : 20.
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Figure 3: Time-dependent uptake of QD/SR9. QDs were premixed
with SR9 at a molecular ratio of 1 : 20. A549 cells were treated with
QD/SR9 at 150 nM QD concentration for 5 min, 20 min, 40 min, 1
hour, and 3 hours. Values are mean ± SD from three independent
experiments. Fluorescence intensity is normalized relative to the
value at 5 min. ∗ P < .01 versus 5 min; α P < .01 versus 20 min;
β P < .01 versus 40 min.

upon removal of medium, the cells were treated with the
QD/SR9 mixture at a final QD concentration of 150 nM for a
designated period of time. After treatment, cells were washed
six times with ice-cold PBS. Phenol red-free medium (2 mL)
(Invitrogen, Carlsbad, CA, USA) was added for fluorescent
image studies.
2.9. Uptake Studies
Energy Inhibition. To determine whether uptake of QD/SR9
is energy dependent, cells were incubated with QD/SR9
under varying metabolic conditions. In temperature studies,
cells were treated at either 37◦ C or 4◦ C. In the low
temperature group, the cells were preincubated at 4◦ C for

Control
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50
Dosage (nM)

100

200

Figure 4: Cell viability of QD/SR9-treated cells. A549 cells were
treated with QD/SR9 (1 : 20) for 24 hours. The concentrations of
QDs used were 12.5, 25, 50, 100, and 200 nM. Values are mean ± SD
from three independent experiments.

30 min and then treated with QD/SR9 at 4◦ C for another 1hour. Cells maintained at 37◦ C comprised the control group.
In metabolic inhibition experiments, cells were incubated in
the absence or presence of a mixture of metabolic inhibitors
(0.15% sodium azide, 15 mM sodium fluoride, and 2 μg/mL
antimycin A). Cells were pretreated with a mixture of
metabolic inhibitors for 1 hour followed by addition of
QD/SR9 to the cells and then incubated for another 1 hour.
Clathrin-Dependant Pathway Inhibition. To disrupt clathrindependent endocytosis, hypertonic challenge, chlorpromazine, and MDC were used. Cells were pretreated with
0.45 M sucrose, 10 μM chlorpromazine, or 25 μg/mL MDC
for 30 min. QD/SR9 was then added to the cells followed by
1 hour incubation.
Caveolin-Dependant Pathway Inhibition. To inhibit caveolindependent endocytosis, filipin and nystatin were used to
deplete cholesterol. Cells were preincubated with 3 μg/ml
filipin and 20 μg/ml nystatin for 30 min before treatment
with QD/SR9 for another 1 hour.
Macropinocytosis Pathway Inhibition. EIPA (30 μM) or Cyt D
(1 μg/mL) was used to block macropinocytosis. Cells were
pretreated with the inhibitor for 30 min before treatment
with QD/SR9 for another 1 hour.
2.10. Small Interfering RNA (siRNA) Transfection. Due to
potential nonspecific eﬀects and toxicity of pharmacological inhibitors, clathrin heavy chain and caveolin-1 siRNA
(Sigma-Aldrich) were used to depress expression of critical
components of the clathrin and caveolar pathways. The sense
and antisense sequences of these siRNA were as follows.
Clathrin HC:
5 -CCCUAAACACCUCAACGAU-3 (sense)
5 -AUCGUUGAGGUGUUUAGGG-3 (antisense).
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Figure 5: SR9 facilitates QD uptake. (a) The relative QD fluorescence intensity in cells exposed to QD or QD/SR9. A549 cells were treated
with 150 nM QDs and 150 nM QD/SR9 (1 : 20) for 5 min, 20 min, 40 min, and 60 min. Fluorescence intensity is normalized relative to QDs
alone at 5 min. (b) and (c) QD fluorescence in cells with and without SR9 after a 5-minute exposure. (d) and (e) QD fluorescence in cells
with and without SR9 after a 1-hour exposure. Images are from a single plane of Z series. Values are mean ± SD from three independent
experiments. Significance is indicated by ∗ P < .01 versus QDs-alone group.

Caveolin-1:
5 -CAUUAUGACCGGGCUCAUA-3 (sense)
5 -UAUGAGCCCGGUCAUAAUG-3 (antisense).

Transfection of siRNA into the A549 cells was performed
at a ∼30% cell confluence. siRNA was complexed with
Lipofectamine 2000 reagent according to the manufacturer’s
instructions (Invitrogen). Western blot and QD/SR9 uptake
studies were conducted 3 days after transfection.
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Figure 6: Energy inhibition reduced internalization of QD/SR9 (150 nM; 1 : 20; 1 hour). (a) Control cells. (b) Cells pretreated at 4◦ C for
30 min then incubated with QD/SR9 for an additional 1 hour. (c) Cells pretreated with a metabolic inhibitor mixture for 1 hour then
incubated with QD/SR9 for an additional 1 hour. Images are from a single plane of Z series. (d) Fluorescence intensity. Values are mean ± SD
from three independent experiments (∗ P  s < .01 versus control).

2.11. Western Blot Analysis. A549 cells were lysed in a buﬀer
comprised of 150 mM sodium chloride, 1.0% Triton X-100,
and 50 mM Tris, pH 8.0, containing 1% protease inhibitor
cocktail (Sigma-Aldrich). The protein concentration was
quantified by the Bradford procedure (BioRad, Hercules,
CA, USA). Ten μg total cell protein was electrophoresed on
8% (clathrin-heavy chain) or 12% (caveolin-1) SDS-PAGE,
followed by electrotransfer to a nitrocellulose membrane.
Clathrin-heavy chain was detected using a mouse monoclonal antibody at a dilution of 1 : 200 and goat antimouse
IgG-HRP secondary antibody (Santa Cruz, CA, USA).
Caveolin-1 protein was detected using a rabbit monoclonal
antibody at a dilution of 1 : 1000 and goat antirabbit IgGHRP secondary antibody (Cell Signaling, Danvers, MA,
USA). The blots were probed with the ECL Western blot
detection system according to the manufacturer’s instructions (Thermo Fisher Scientific, Rockford, IL, USA). The
ImageJ software (NIH) was used for quantitative analysis of
the Western blot.
2.12. Epifluorescent Microscopy. After treatment with
QD/SR9, cells were viewed with an Olympus IX51 inverted
microscope at 600X total magnification using a UPLFLN
60X NA 1.25 objective (Olympus, Center Valley, PA, USA).
QD filter set (EX 435/40, EM 519-700) was used for QDs
(Semrock, Rochester, NY, USA). Images were captured with

a Hamamatsu ORCA285 CCD camera. Z series images of
the entire cell volume were taken at 0.3 μm internals . Images
were analyzed using SlideBook software (Intelligent Imaging
Innovations, Denver, CO, USA).
2.13. Statistical Analyses. Data were expressed as the
mean ± standard deviation from three independent experiments. Fluorescent intensity was quantified using SlideBook
software. The mean fluorescence intensity (after background
subtraction) of a single plane in Z series was recorded. Onetailed unpaired Student’s t-test was used for significance
testing, using P = .05.

3. Results
3.1. Formation of QD/SR9 Noncovalent Binding. To test
whether SR9 peptide stably associated with QDs, QDs
were mixed with SR9 at various molecular ratios (1 : 10,
1 : 20, 1 : 30, and 1 : 60). These mixtures were separated by
electrophoresis in a 0.6% agarose gel (Figure 1). QD mobility
decreased as the amount of SR9 increased. This indicated the
formation of noncovalent QD/SR9 complexes.
3.2. Molecular Ratio of QD and SR9 Aﬀects QD Uptake. To
determine the optimal ratio for cellular uptake, A549 cells
were incubated with QDs (150 nM) preincubated with SR9
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Figure 7: Eﬀect of clathrin inhibitors on QD/SR9 internalization (150 nM; 1 : 20; 1 hour). (a) Control cells. (b) Cells pretreated with
chlorpromazine for 30 min then incubated with QD/SR9 for an additional 1 hour. (c) Cells pretreated with MDC for 30 min then incubated
with QD/SR9 for an additional 1 hour. Images are from a single plane of Z series. (d) Fluorescence intensity. Values are mean ± SD from
three independent experiments (∗ P  s < .01 versus control).

at diﬀerent molecular ratios. QD uptake was increased as
the ratio of SR9 increased from 1 : 10 to 1 : 30 (P  s < .01)
(Figure 2). However, there was no increase in the amount
of internalization at ratios above 1 : 30. Although the uptake
reaches the highest level at 1 : 30, good imaging quality can
be obtained at 1 : 20. Further, in the future we intend to use
this system to carry cargoes which requires binding sites on
quantum dots. Accordingly, we chose to use 1 : 20 as the ratio
between QDs and SR9.
3.3. Time-Dependent Uptake. To determine the optimal
dosing time, A549 cells were incubated with QD/SR9 (1 : 20)
for 5 min, 20 min, 40 min, 1 hour, and 3 hours. Compared to
the 5-minute group, the uptake of QD/SR9 was increased by
1.67 ± 0.37-fold in 20 min (P  s < .01) (Figure 3). The uptake
was near maximal at 1-hour. Accordingly, the 1 hour uptake
time point was used in subsequent experiments.
3.4. Cytotoxicity of QD/SR9. To assess the cytotoxicity of
QD/SR9 complex, A549 cells were exposed to QD/SR9
(1 : 20) complex at various QD concentrations for 24 hours.
No cytotoxicity of QD/SR9 was observed at concentrations
up to 200 nM (Figure 4).
3.5. Cellular Uptake of QDs Facilitated by SR9 Peptide. To
determine the ability of SR9 peptide to facilitate QD delivery,
A549 cells were treated with 150 nM QDs alone or 150 nM

QDs premixed with SR9 at a ratio of 1 : 20. After incubation
of 5 min, 20 min, 40 min, and 60 min, QDs-treated cells were
observed under an epifluorescence microscope. Images taken
using the same exposure time show that enhanced uptake of
the QD/SR9 complex was observed compared to QD alone
(Figures 5(b)–5(e)). Quantitation of fluorescence intensities
shows that compared with QD alone in five minutes, the
uptake of QD/SR9 increased by 3–8-folds (Figure 5(a)).
3.6. Mechanism of QD/SR9 Internalization. Endocytosis,
an essential cellular process for internalizing extracellular
materials, utilizes several distinct pathways. To determine
the mechanism of SR9-mediated QD delivery, a series of
inhibition studies were carried out.
3.6.1. Energy-Dependent Studies. To determine whether
uptake of QD/SR9 is mediated by energy-dependent endocytosis, we used low temperature or a mixture of metabolic
inhibitors to deplete intracellular energy (Figure 6). In the
low temperature study, the cells were incubated with QD/SR9
at 37◦ C or 4◦ C. As shown in Figures 6(a) and 6(b), QD/SR9
internalization was significantly impeded at 4◦ C; the fluorescence intensity at 4◦ C was 73 ± 11.5% lower than that at 37◦ C
(P < .01) (Figure 6(d)). In the metabolic inhibition study,
A549 cells were incubated with QD/SR9 in the presence or
absence of a mixture of metabolic inhibitors (0.15% sodium
azide, 15 mM sodium fluoride, and 2 μg/mL antimycin A).
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Figure 8: Lipid raft/caveolin inhibition decreased QD/SR9 internalization (150 nM; 1 : 20; 1 hour). (a) Control cells. (b) Cells pretreated
with nystatin for 30 min then incubated with QD/SR9 for an additional 1 hour. (c) Cells pretreated with filipin for 30 min then incubated
with QD/SR9 for an additional 1 hour. Images are from a single plane of Z series. (d) Fluorescence intensity. Values are mean ± SD from
three independent experiments (∗ P  s < .01 versus control).

These metabolic inhibitors strongly inhibited the uptake of
QD/SR9 (Figures 6(a) and 6(c)). The fluorescent intensity
in the presence of metabolic inhibitors was 61 ± 5.7% lower
than that in the control group (P < .01) (Figure 6(d)).
3.6.2. Clathrin-Dependent Pathway. To perturb the clathindependent uptake pathway, three methods were used: monodansylcadaverine (MDC), hypertonic sucrose, and chlorpromazine. The inhibitory activity of MDC is attributed to
the stabilization of nascent clathrin-coated vesicles, which
limits new clathrin-coated vesicle production [20]. The
underlying mechanism of hypertonic sucrose involves the
dispersion of clathrin lattices on the plasma membrane
[21]. Chlorpromazine is a cationic amphipathic drug that
relocates clathrin and adaptor protein complex-2 (AP-2)
from the plasma membrane to the endosomal membrane
[22]. MDC reduced the uptake of QD/SR9 by 44 ± 13.0%
(P < .01) while hypertonic medium decreased uptake by 59%
(P < .01; data not shown). In contrast, chlorpromazine only
slightly reduced uptake by 14 ± 12.1% (P > .05) (Figure 7).
3.6.3. Lipid Raft/Caveolin-Dependent Pathway. Nystatin and
filipin, lipid raft inhibitors, are used to block the caveolindependent endocytic pathway [23, 24]. Treatment of cells
with these two inhibitors reduced the QD/SR9 internalization by 32 ± 8.6% and 35 ± 15.5%, respectively, (P  s < .01)
(Figure 8), indicating that a lipid raft-dependent process is
involved in QD/SR9 internalization.

3.6.4. Macropinocytosis Pathway. 5-(N-ethyl-N-isopropyl)
amiloride (EIPA) is an inhibitor of the Na+ /H+ exchange
that is required for macropinocytosis [25]. Cytochalasin D
(Cyt D) is an F-actin depolymerizing drug that caps the
barbed, faster-growing ends of actin filaments [26]. EIPA
reduced the uptake of QD/SR9 by 47 ± 14.3% (P < .01)
(Figure 9). To confirm the eﬀective concentration of Cyt
D, we used Alexa 568—phalloidin to stain actin of Cyt
D-treated and control cells. Actin was depolymerized in
A549cells by 1 μg/mL Cyt D (data not shown). Cyt D
significantly reduced the uptake of QDs (P < .01) (Figure 9).
Condensed green fluorescent agglomerates were observed
around the cellular surface following treatment with Cyt D
(Figure 9(c)).
3.7. siRNA Knockdown. To complement the use of pharmacological inhibitors, we used the RNAi techniques to
eliminate expression of specific components of the various
uptake mechanisms. Clathrin HC and caveolin-1 siRNA
were used to knock down clathrin-dependent and caveolindepedent pathways, respectively. The Western blot experiments demonstrated the results of the knockdown treatment
(Figure 10). The protein expression of clathrin and caveolin1 was reduced by 93 ± 7.2% and 73 ± 5.7%, respectively,
(P  s < .01). Following clathrin HC or caveolin-1 protein
knockdown, the uptake of QD/SR9 was not significantly
aﬀected (Figure 11).
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Figure 9: Macropinocytosis inhibition perturbed QD/SR9 internalization (150 nM; 1 : 20; 1 hour). (a) Control cells. (b) Cells pretreated
with EIPA for 30 min then incubated with QD/SR9 for an additional 1 hour. (c) Cells pretreated with Cyt D for 30 min then incubated with
QD/SR9 for an additional 1 hour. Images are from a single plane of Z series. (d) Fluorescence intensity. Values are mean ± SD from three
independent experiments (∗ P  s < .01 versus control).

4. Discussion
Quantum dots are an emerging class of fluorescent probes
for cellular imaging. In comparison with organic dyes and
fluorescent proteins, QDs have unique properties, including
high quantum yield and photostability, which make them
better suited for delivering and monitoring biomolecules.
The eﬃciency of internalizing QDs can be improved by
incorporating cell-penetrating peptides [5]. Accordingly, our
goals were to test whether nona-arginine (SR9) facilitates
QD uptake and to determine the mechanism of this uptake.
Data from this study demonstrate that QDs are internalized
into A549 cells within 5 min with the aid of SR9; without
SR9, QD uptake is minimal (Figure 5). The enhancement
of internalization by basic protein transducers is thought to
reflect an electrostatic interaction between cationic nonaarginine and the negatively charged polar heads of the
phospholipids of the plasma membrane [18]. Our study
demonstrates that SR9 can significantly increase QD uptake.
QD/SR9 internalization was dramatically blocked by
either low temperature or a mixture of metabolic inhibitors.
This indicates that the uptake of QD/SR9 is highly energydependent and supports the notion that endocytosis is
the major uptake process. Since endocytosis encompasses
numerous pathways, our subsequent studies were designed
to further elucidate the specific mechanism of uptake.

Clathrin-dependent endocytosis is a well-characterized
endocytic pathway. To determine the role of clathrinmediated uptake of QD/SR9, we used three diﬀerent
inhibitors. Treating cells with hypertonic sucrose significantly reduced QD/SR9 uptake. Although this kind of
inhibition is considered evidence of clathrin-dependent
endocytosis, recent studies have suggested that it also
interferes with other internalization pathways, including
caveolin-dependent endocytosis and macropinocytosis [27].
Accordingly, the eﬀects of two additional inhibitors, MDC
and chlorpromazine, were determined. MDC significantly
impeded QD/SR9 internalization. Though MDC is considered as a clathrin pathway inhibitor, it is also a macropinocytosis inhibitor via suppression of the transglutaminase family
that activates Rho GTPases, the key regulators of actin
assembly and dynamics [27]. Thus, MDC might block actindependent pathways such as macropinocytosis. Chlorpromazine had only a small eﬀect on uptake. Due to the varying
results and possible oﬀ-target eﬀects of the inhibitor studies,
we used siRNA to knock down clathrin heavy chain. The
Western blot analysis indicated that near complete clathrin
protein (93 ± 5.7%) expression was suppressed. The almost
complete loss of clathrin did not aﬀect the QD fluorescence
intensity inside cells relative to control levels. Together,
our data suggest that clathrin-mediated endocytosis is not
required for QD/SR9 internalization. However, because
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Figure 10: Western blot analysis of clathrin HC and caveolin-1 protein after siRNA treatment. A549 cells were treated with siRNA of clathrin
HC or caveolin-1 protein for 3 days, and then cells were lysed for Western blot analysis. (a) Clathrin HC protein expression in A549 cells.
(b) Caveolin-1 protein expression in A549 cells. β-actin was used as the internal control. (c) and (d) Quantification analysis of the Western
blots. Intensity is normalized to the siRNA untreated group. Values are mean ± SD from three independent experiments (∗ P  s < .01 versus
control).

clathrin protein was not completely eliminated, we cannot
rule out that clathrin is involved in QD/SR9 uptake.
Nystatin and filipin are polyene antibiotics that accumulate cholesterol and thereby sequester lipid from cell membranes. Nystatin and filipin are highly selective inhibitors
of the lipid raft-dependent pathway because of this lipid
sequestering [23, 24]. Both inhibitors hindered the uptake
of QD/SR9, suggesting that the internalization was lipid raft
dependent. Cholesterol depletion could result in blockage of
several lipid raft-dependent endocytic pathways, including

caveolae-dependent and macropinocytic pathways [24]. For
further clarification, caveolin-1 siRNA was used to knockdown caveolin-1 expression. The Western blot analysis and
live cell imaging indicated that internalization of QD/SR9
was not reduced while caveolin-1 protein was knocked
down by 73 ± 7.2%. These findings suggest that QD/SR9
internalization is a lipid raft-dependent process that is
not mainly caveolin-mediated. Because caveolin-1 protein
was not completely knock down, we cannot rule out that
caveolin-1 was involved in QD/SR9 uptake.
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Figure 11: QD/SR9 uptake after knockdown of clathrin HC and caveolin-1 protein (150 nM; 1 : 20; 1 hour). A549 cells were treated with
siRNA of clathrin HC or caveolin-1 protein for 3 days, and then cells were used for uptake studies. (a) Control cells. (b) Cells pretreated with
clathrin HC siRNA. (c) Cells pretreated with caveolin-1 siRNA. Images are from a single plane of Z series. (d) Fluorescence intensity. Values
are mean ± SD from three independent experiments.

Macropinocytosis is a rapid, lipid raft-dependent, and
receptor-independent form of endocytosis. Macropinocytosis includes three essential steps: actin cytoskeleton-driven
ruﬄe formation, closure of the ruﬄe into a vesicle, and
dissociation of actin filaments from the vesicle [28]. The
fluorescent intensities in cells treated with two macropinocytosis inhibitors, EIPA and Cyt D, were significantly reduced
compared to the control cells. It is worth noting that in
Cyt D-treated cells, QD/SR9 was densely localized around
cellular surfaces, not in cytosol, leading to overestimate of
QD/SR9 internalization. This is similar with the observation
of Nakase et al. that cellular R8 peptide was predominantly
localized in cellular boundaries with very little punctuate
staining in Cyt D-treated cells [29]. Ruan et al. made a similar
observation with Cyt D-treated cells [6]. It is unclear how the
dense aggregates aﬀect quantitation. In summary the uptake
of QD/SR9 is lipid raft-dependent macropinocytosis.
Collectively, our data show that SR9 facilitates a rapid
energy-dependent cellular entry of QDs. The internalization
involves lipid raft and depends on macropinocytosis. Other
pathways such as RhoA-dependent and CDC42-dependent
endocytic pathways may also deserve attention [30, 31].
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